news bytes
tuberculosis. The molecules target
an important gene, IdeR, which
is essential for the survival of
the bacteria. This development
could lead to new drugs against
TB in future. “We have identified
inhibitory molecules against IdeR,
a key iron regulator that is crucial
for survival of the TB pathogen,”
said Prof. Anil K. Tyagi, a senior
scientist at the University of Delhi
and lead researcher of the study.
The findings have been published
in the journal Scientific Reports.
In laboratory studies, the new
molecules were not toxic in human
liver cells and kidney cells and
could efficiently reach the bacteria
present within the cell, researchers
said.
BIOCON & MYLAN’S PROPOSED
BIOSIMILAR ‘TRASTUZUMAB’
GETS USFDA NOD
Drugs Advisory Committee (ODAC)
recommended approval of the
companies’ proposed biosimilar
trastuzumab. The committee
voted 16-0 in support of eligible
indications of the reference
product, Herceptin, which include
HER2-positive breast cancer in the
metastatic and adjuvant settings.
Mylan and Biocon are exclusive
partners on a broad portfolio of
biosimilar and insulin products.
The proposed biosimilar
trastuzumab is one of the six
biologic products co-developed by
Mylan and Biocon for the global
marketplace. Mylan has exclusive
commercialization rights for the
proposed biosimilar trastuzumab in
the U.S., Canada, Japan, Australia,
New Zealand and in the European
Union and European Free Trade
Association countries. Biocon has
co-exclusive commercialization
rights with Mylan for the product in
the rest of the world.
GOVT SAYS NO SHORTAGE
OF ESSENTIAL DRUGS POST
INTRODUCTION OF GST
Biocon Limited has announced
that the U.S. Food and Drug
Administration (FDA) Oncologic
90
BioVoiceNews | August 2017
The Minister of State for Chemicals
and Fertilizers, Mr Mansukh L.
Mandaviya, in a written reply
to a question in Parliament,